公开(公告)号：AT547102T

公开(公告)日：2012-03-15

申请号：AT06750554

申请日：2006-04-17

Applicant: PTC THERAPEUTICS INC

Inventor： LENNOX WILLIAM JOSEPH ,  CHOI SOONGYU ,  DAVIS THOMAS ,  HWANG SEONGWOO ,  CORSON DONALD THOMAS ,  QI HONGYAN ,  MOON YOUNG-CHOON ,  CAO LIANGXIAN ,  ARASU TAMIL

IPC: A61K31/497 ,  A61K31/337 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4745 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/5513 ,  A61K31/724

Abstract: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing plasma and/or tumor VEGF levels, are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the treatment of cancer, and the reduction of plasma and/or tumor VEGF levels, using the compounds of the invention.

公开(公告)号：AU2005222632B2

公开(公告)日：2012-02-09

申请号：AU2005222632

申请日：2005-03-15

Applicant: PTC THERAPEUTICS INC

Inventor： CAO LIANGXIAN ,  CHOI SOONGYU ,  QI HONGYAN ,  LENNOX WILLIAM JOSEPH ,  CORSON DONALD THOMAS ,  TAMILARASU NADARAJAN ,  MOON YOUNG-CHOON ,  HWANG SEONGWOO

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/4745 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/541 ,  A61K31/551 ,  A61K31/724

Abstract: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the inhibition of angiogenesis, and/or in the treatment of cancer, diabetic retinopathy or exudative macular degeneration are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the inhibition of angiogenesis, and/or the treatment of cancer, diabetic retinopathy or exudative macular degeneration using the compounds of the invention.

公开(公告)号：NZ543263A

公开(公告)日：2008-12-24

申请号：NZ54326304

申请日：2004-04-09

Applicant: PTC THERAPEUTICS INC

Inventor： KARP GARY MITCHELL ,  HWANG SEONGWOO ,  CHEN GUANGMING ,  ALMSTEAD NEIL GREGORY ,  MOON YOUNG-CHOON

IPC: A61K31/4245 ,  C07D271/06 ,  C07D271/12 ,  C07D413/04 ,  C07D413/10 ,  A61P43/00 ,  A61P35/00

Abstract: Disclosed is a compound of formula (I), wherein the substituents are as defined in the specification. The compounds are modulators of premature translation termination or nonsense-mediated mRNA decay and are useful in the treatment of genetic diseases such as autoimmune diseaases, blood diseases, collagen diseases, diabetes, inflammatory diseases and central nervous system diseases including arthritis, rheumatoid arthritis, graft versus host disease, multiple sclerosis, muscular dystrophy, late infantile neuronal ceroid lipofuscinosis, Duchenne muscular dystrophy, Alzheimer's disease, Tay Sachs disease, neurodegenerative diseases, Parkinson's disease, hemophilia, Von Willebrand disease, ataxia-telangiectasia, beta-thalassemia, kidney stones, osteogenesis imperfecta, cirrhosis, familial polycythemia, immunodeficiency, kidney disease, cystic fibrosis, familial hypercholesterolemia, retinitis pigmentosa, amyloidosis, atherosclerosis, giantism, dwarfism, hypothyroidism, hyperthyroidism, aging, obesity, Niemann Pick's disease, Marfan syndrome and cancer.

公开(公告)号：BRPI0508814A

公开(公告)日：2007-08-07

申请号：BRPI0508814

申请日：2005-03-15

Applicant: PTC THERAPEUTICS INC

Inventor： MOON YOUNG-CHOON ,  CAO LIANGXIAN ,  TAMILARASU NADARAJAN ,  QI HONGYAN ,  CHOI SOONGYU ,  LENNOX WILLIAM JOSEPH ,  CORSON DONALD THOMAS ,  HWANG SEONGWOO

IPC: A61K31/497 ,  A61K31/437 ,  A61K31/4745 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/541 ,  A61K31/551 ,  A61K31/724 ,  A61P35/00 ,  C07D471/04

Abstract: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the inhibition of angiogenesis, and/or in the treatment of cancer, diabetic retinopathy or exudative macular degeneration are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the inhibition of angiogenesis, and/or the treatment of cancer, diabetic retinopathy or exudative macular degeneration using the compounds of the invention.

公开(公告)号：MX2007006180A

公开(公告)日：2007-06-20

申请号：MX2007006180

申请日：2005-11-23

Applicant: PTC THERAPEUTICS INC

Inventor： QI HONGYAN ,  MOON YOUNG-CHOON ,  CAO LIANGXIAN ,  TAMILARASU NADARAJAN ,  LENNOX WILLIAM JOSEPH ,  CHOI SOONGYU ,  HWANG SEONGWOO

IPC: C07D209/88 ,  C07D209/94 ,  C07D213/82 ,  C07D239/42 ,  C07D261/14 ,  C07D263/32 ,  C07D271/10 ,  C07D285/06 ,  C07D307/68 ,  C07D307/84 ,  C07D317/66 ,  C07D333/38 ,  C07D487/22 ,  C07D495/04 ,  C07D498/22

Abstract: De conformidad con la presente invencion, han sido identificados los compuestos que inhiben la expresion de FCEV post-transcripcionalmente, y se han provisto los metodos para su uso; en un aspecto de la invencion, se proveen los compuestos y composiciones utiles en la inhibicion de la produccion de FCEV, y/o en la inhibicion de la angiogenesis, y/o en el tratamiento del cancer, retinopatia diabetica o degeneracion macular exudativa; en otro aspecto de la invencion, se proveen los metodos para la inhibicion de la produccion de FCEV, la inhibicion de la angiogenesis, y/o el tratamiento del cancer, retinopatia diabetica o degeneracion macular exudativa utilizando los compuestos de la invencion.

公开(公告)号：MXPA06010543A

公开(公告)日：2007-03-26

申请号：MXPA06010543

申请日：2005-03-15

Applicant: PTC THERAPEUTICS INC

Inventor： QI HONGYAN ,  MOON YOUNG-CHOON ,  CAO LIANGXIAN ,  TAMILARASU NADARAJAN ,  LENNOX WILLIAM JOSEPH ,  CORSON DONALD THOMAS ,  CHOI SOONGYU ,  HWANG SEONGWOO

IPC: A61K31/497 ,  A61K31/437 ,  A61K31/4745 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/541 ,  A61K31/551 ,  A61K31/724 ,  A61P35/00 ,  C07D471/04

Abstract: De acuerdo con la presente invencion, han sido identificados los compuestos que inhiben la expresion de VEGF post transcripcionalmente, y se proveen metodos para su uso; en un aspecto de la invencion, se proveen utiles en la inhibicion de la produccion de VEGF, en la inhibicion de angiogenesis y/o en el tratamiento de cancer, retinopatia diabetica o degeneracion macular exudativa; en otro aspecto de la invencion, se proveen metodos para la inhibicion de la produccion de VEGF, la inhibicion de la angiogenesis, y/o el tratamiento de cancer, retinopatia diabetica o degeneracion macular exudativa usando los compuestos de la invencion.

公开(公告)号：NO20055314A

公开(公告)日：2006-01-04

申请号：NO20055314

申请日：2005-11-10

Applicant: PTC THERAPEUTICS INC

Inventor： KARP GARY MITCHELL ,  HWANG SEONGWOO ,  CHEN GUANGMING ,  ALMSTEAD NEIL GREGORY ,  MOON YOUNG-CHOON

IPC: C07D271/06 ,  A61K31/4245 ,  C07D271/12 ,  C07D413/04 ,  C07D413/10

CPC classification number: A61K31/4245 ,  A61K9/0053 ,  A61K9/12 ,  A61K9/48 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/655 ,  A61K45/06 ,  A61P27/02 ,  C07D271/06 ,  C07D271/12 ,  C07D285/14 ,  C07D413/02 ,  C07D413/04 ,  C07D413/10

Abstract: The present invention relates to a compound 3-[5-(2-Fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, having the structure: or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition and a single unit dosage thereof, as well as the said compound for use in a method of treating, preventing or ameliorating diseases as defined herein.

公开(公告)号：NO20055314D0

公开(公告)日：2005-11-10

申请号：NO20055314

申请日：2005-11-10

Applicant: PTC THERAPEUTICS INC

Inventor： KARP GARY MITCHELL ,  HWANG SEONGWOO ,  CHEN GUANGMING ,  ALMSTEAD NEIL GREGORY

IPC: A61K31/4245 ,  C07D271/06 ,  C07D271/12 ,  C07D413/04 ,  C07D413/10 ,  C07D

Abstract: Provided herein is a compound of formulaor a pharmaceutically acceptable salt thereof for use in a method for treating a lysosomal storage disorder associated with a premature stop codon in a patient.

公开(公告)号：AU2004229487A1

公开(公告)日：2004-10-28

申请号：AU2004229487

申请日：2004-04-09

Applicant: PTC THERAPEUTICS INC

Inventor： CHEN GUANGMING ,  KARP GARY MITCHELL ,  HWANG SEONGWOO ,  ALMSTEAD NEIL GREGORY

IPC: A61K31/4245 ,  C07D271/06 ,  C07D271/12 ,  C07D413/04 ,  C07D413/10

Abstract: Provided herein is a compound of formulaor a pharmaceutically acceptable salt thereof for use in a method for treating a lysosomal storage disorder associated with a premature stop codon in a patient.

公开(公告)号：CA2493458A1

公开(公告)日：2004-01-29

申请号：CA2493458

申请日：2003-07-23

Applicant: PTC THERAPEUTICS INC

Inventor： CHEN GUANGMING ,  HWANG SEONGWOO ,  WILDE RICHARD G ,  TAKASUGI JAMES J ,  WELCH ELLEN M

IPC: A61K31/17 ,  A61K31/4166 ,  A61P35/00 ,  C07C275/42 ,  C07D233/32 ,  C07D233/42 ,  C07D233/70 ,  C07D233/72 ,  C07D233/78 ,  C07D233/84 ,  C07D285/16 ,  C07D401/04 ,  C07D401/10 ,  C07D405/04 ,  C07D405/06 ,  C07D409/04 ,  C07D285/06 ,  C07D403/10 ,  C07D409/10

Abstract: The invention encompasses ureido substituted benzoic acid compounds of structure (I), compositions comprising the compounds and methods for treatin g or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions.